NasdaqGM:NAMSBiotechs
NewAmsterdam Pharma (NAMS) Earnings Losses Raise The Question Of Whether The Stock Is A Bargain
NewAmsterdam Pharma earnings jolt investor focus
NewAmsterdam Pharma (NasdaqGM:NAMS) moved into the spotlight after its latest earnings report showed second quarter sales of US$3.7 million and a net loss of US$64.14 million, sharpening attention on its financial trajectory.
See our latest analysis for NewAmsterdam Pharma.
The recent earnings report landed against a weak share price backdrop for NewAmsterdam Pharma, with a 30 day share price return of down 15.63% and a year to date share price...